

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3966421

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST
CONVEYING PARTY DATA	
Name	Execution Date
ATON PHARMA, INC.	07/18/2016
BAUSCH & LOMB INCORPORATED	07/18/2016
BAUSH & LOMB PHARMA HOLDINGS CORP.	07/18/2016
DENDREON PHARMACEUTICALS, INC.	07/18/2016
DOW PHARMACEUTICAL SCIENCES, INC.	07/18/2016
MEDICIS PHARMACEUTICAL CORPORATION	07/18/2016
OBAGI MEDICAL PRODUCTS, INC.	07/18/2016
OMP, INC.	07/18/2016
ORAPHARMA, INC.	07/18/2016
PRECISION DERMATOLOGY, INC.	07/18/2016
SALIX PHARMACEUTICALS, INC.	07/18/2016
SALIX PHARMACEUTICALS, LTD	07/18/2016
SANTARUS, INC.	07/18/2016
SOLTA MEDICAL, INC.	07/18/2016
VALEANT CANADA LP, BY ITS GENERAL PARTNER VALEANT CANADA GP LIMITED	07/18/2016
VALEANT PHARMACEUTICALS INTERNATIONAL, INC.	07/18/2016
VALEANT HOLDINGS IRELAND (AS SUCCESSOR TO VALEANT INTERNATIONAL BERMUDA)	07/18/2016
VALEANT PHARMACEUTICALS NORTH AMERICA LLC	07/18/2016
VALEANT PHARMACEUTICALS IRELAND	07/18/2016
RECEIVING PARTY DATA	
Name:	BARCLAYS BANK PLC
Street Address:	745 SEVENTH AVENUE
Internal Address:	27TH FLOOR
City:	NEW YORK
State/Country:	NEW YORK
Postal Code:	10019
PROPERTY NUMBERS Total: 160	

Property Type	Number
Patent Number:	6683046
Application Number:	14087864
Application Number:	14455116
Patent Number:	8753389
Patent Number:	8512014
Application Number:	13917734
Patent Number:	8637514
Patent Number:	8637515
Patent Number:	9039174
Application Number:	14630700
Patent Number:	8690320
Patent Number:	9091864
Application Number:	13661493
Patent Number:	8889160
Patent Number:	9375401
Application Number:	14519776
Patent Number:	8530641
Patent Number:	8604020
Patent Number:	8931900
Application Number:	13835237
Patent Number:	8967799
Application Number:	14020386
Application Number:	13480651
Application Number:	13606362
Patent Number:	9279095
Patent Number:	9249249
Patent Number:	8807745
Patent Number:	9075187
Application Number:	14427928
Application Number:	14772106
Patent Number:	D702745
Patent Number:	D702746
Application Number:	14416229
Application Number:	14416154
Application Number:	14072859
Patent Number:	9155615
Patent Number:	9237947
Application Number:	13957497

Property Type	Number
Patent Number:	9001316
Patent Number:	9309357
Application Number:	14513459
Application Number:	14690791
Application Number:	15006525
Application Number:	14082662
Application Number:	14604543
Application Number:	62242113
Application Number:	14340367
Application Number:	14505379
Patent Number:	8809307
Application Number:	14552307
Patent Number:	8663699
Application Number:	14260211
Patent Number:	8895070
Patent Number:	9078870
Application Number:	13613401
Application Number:	13352712
Application Number:	14216722
Patent Number:	8486978
Patent Number:	9302009
Application Number:	14491889
Application Number:	14755699
Application Number:	13478249
Application Number:	13890173
Application Number:	14213530
Application Number:	14641089
Patent Number:	9078889
Application Number:	14796296
Patent Number:	7902246
Application Number:	13672520
Application Number:	13536130
Application Number:	13659789
Patent Number:	7390431
Patent Number:	7560119
Patent Number:	7445729
Patent Number:	7556820
Patent Number:	7687650

Property Type	Number
Patent Number:	7897800
Patent Number:	8148563
Patent Number:	7927614
Patent Number:	7867522
Application Number:	14026592
Patent Number:	8273791
Patent Number:	8505730
Application Number:	13368915
Application Number:	13144833
Application Number:	14849413
Application Number:	13942419
Application Number:	13942445
Application Number:	13975898
Application Number:	14603932
Application Number:	14897516
Patent Number:	9364467
Application Number:	14585911
Application Number:	14424515
Application Number:	14629873
Application Number:	14629871
Application Number:	14629869
Application Number:	14282888
Application Number:	14448872
Application Number:	14529012
Application Number:	14731692
Application Number:	14799018
Patent Number:	D715422
Application Number:	14933253
Application Number:	14882934
Application Number:	14995791
Application Number:	62294405
Application Number:	13981699
Application Number:	14379095
Application Number:	14673670
Application Number:	14074927
Application Number:	14353231
Patent Number:	5962731
Patent Number:	5929105

Property Type	Number
Patent Number:	6153639
Patent Number:	6756396
Patent Number:	7122569
Patent Number:	6117862
Patent Number:	7850981
Patent Number:	6800086
Patent Number:	7753943
Patent Number:	8106038
Patent Number:	7455858
Application Number:	14945865
Application Number:	15006943
Application Number:	15173961
Patent Number:	6274614
Patent Number:	6677366
Patent Number:	7015240
Patent Number:	6043237
Patent Number:	6248734
Patent Number:	6984395
Patent Number:	8852629
Patent Number:	8862224
Patent Number:	9226917
Application Number:	14489863
Patent Number:	8492588
Application Number:	13863529
Application Number:	14629176
Patent Number:	6013053
Patent Number:	8158669
Patent Number:	8034803
Patent Number:	7060695
Patent Number:	9211214
Application Number:	14872248
Patent Number:	6599891
Application Number:	14474580
Patent Number:	8604085
Application Number:	11791603
Application Number:	14002438
Patent Number:	7226455
Patent Number:	8393735

Property Type	Number
Application Number:	13881686
Patent Number:	8877792
Patent Number:	8075875
Patent Number:	8334328
Application Number:	14816333
Application Number:	13895305
Patent Number:	9271973
Patent Number:	9050313

CORRESPONDENCE DATA

Fax Number: (212)735-2000

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 212-735-2811

Email: mrribando@skadden.com

Correspondent Name: SKADDEN, ARPS, SLATE, MEAGHER & FLOM

Address Line 1: FOUR TIMES SQUARE

Address Line 2: MONIQUE L. RIBANDO

Address Line 4: NEW YORK, NEW YORK 10036

NAME OF SUBMITTER:	PAIGE M. AMUNDSON
---------------------------	-------------------

SIGNATURE:	/Paige M. Amundson/
-------------------	---------------------

DATE SIGNED:	07/18/2016
---------------------	------------

Total Attachments: 15

source=Patent Security Agreement#page1.tif
source=Patent Security Agreement#page2.tif
source=Patent Security Agreement#page3.tif
source=Patent Security Agreement#page4.tif
source=Patent Security Agreement#page5.tif
source=Patent Security Agreement#page6.tif
source=Patent Security Agreement#page7.tif
source=Patent Security Agreement#page8.tif
source=Patent Security Agreement#page9.tif
source=Patent Security Agreement#page10.tif
source=Patent Security Agreement#page11.tif
source=Patent Security Agreement#page12.tif
source=Patent Security Agreement#page13.tif
source=Patent Security Agreement#page14.tif
source=Patent Security Agreement#page15.tif

PATENT SECURITY AGREEMENT

This **PATENT SECURITY AGREEMENT**, dated as of July 18, 2016 (as it may be amended, restated, supplemented or otherwise modified from time to time, this “**Agreement**”), is made by each of the entities identified as a grantor on the signature pages hereto (the “**Grantors**”) in favor of Barclays Bank PLC, as collateral agent for the Secured Parties (in such capacity, together with its successors and permitted assigns, the “**Collateral Agent**”).

WHEREAS, the Grantors are subject to, and are made party to, the Pledge and Security Agreement, dated as of June 29, 2011, as amended by the Amended and Restated Pledge and Security Agreement dated as of October 20, 2011, and as further amended by the Second Amended and Restated Pledge and Security Agreement, dated as of February 13, 2012 (as it may be amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “**Pledge and Security Agreement**”), between the Grantors and the other grantors party thereto and the Collateral Agent pursuant to which the Grantors granted a security interest to the Collateral Agent in the Patent Collateral (as defined below) and are required to execute and deliver this Agreement.

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Grantors hereby agree with the Collateral Agent as follows:

SECTION 1. Defined Terms

Unless otherwise defined herein, terms defined in the Pledge and Security Agreement and used herein have the respective meanings given to them in the Pledge and Security Agreement.

SECTION 2. Grant of Security Interest in Patent Collateral

Each Grantor hereby grants to the Collateral Agent, for the benefit of the Secured Parties, a security interest in and continuing lien on all of such Grantor’s right, title and interest in, to and under the following, in each case whether now owned or hereafter acquired by such Grantor or in which such Grantor now has or hereafter acquires any right, title or interest and wherever the same may be located (collectively, the “**Patent Collateral**”):

all United States and foreign patents and certificates of invention, or similar industrial property rights, and applications for any of the foregoing, including, but not limited to: (i) each patent and patent application listed in Schedule A attached hereto, (ii) all reissues, divisions, continuations, continuations-in-part, extensions, renewals and reexaminations thereof, (iii) all patentable inventions and improvements thereto, (iv) the right to sue or otherwise recover for any past, present and future infringement or other violation thereof, (v) all Proceeds of the foregoing, including, without limitation, license fees, royalties, income, payments, claims, damages and proceeds of suit now or hereafter due and/or payable with respect thereto, and (vi) all other rights of any kind accruing thereunder or pertaining thereto throughout the world, but in any case excluding any Excluded Assets.

SECTION 3. Security Agreement

The security interest granted pursuant to this Agreement is granted in conjunction with the security interest granted to the Collateral Agent for the Secured Parties pursuant to the Pledge and Security Agreement, and each Grantor hereby acknowledges and affirms that the rights and remedies of

the Collateral Agent with respect to the security interest in the Patent Collateral made and granted hereby are more fully set forth in the Pledge and Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein. In the event that any provision of this Agreement is deemed to conflict with the Pledge and Security Agreement, the provisions of the Pledge and Security Agreement shall control.

SECTION 4. Governing Law

THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO CONFLICT OF LAWS PRINCIPLES THEREOF.

SECTION 5. Counterparts


This Agreement may be executed in one or more counterparts and by different parties hereto in separate counterparts, each of which when so executed and delivered shall be deemed an original, but all such counterparts together shall constitute but one and the same instrument. Delivery of an executed counterpart to this Agreement by facsimile transmission or other electronic transmission (such as .pdf or .tif) shall be effective as delivery of a manually signed counterpart of this Agreement.

[Remainder of page intentionally left blank]


IN WITNESS WHEREOF, each Grantor has caused this Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

Grantors:


ATON PHARMA, INC.

By: 
Name: Linda A. LaGorga
Title: SVP, Treasurer


BAUSCH & LOMB INCORPORATED

By: 
Name: Linda A. LaGorga
Title: SVP, Treasurer


BAUSCH & LOMB PHARMA HOLDINGS CORP.

By: 
Name: Linda A. LaGorga
Title: Treasurer


DENDREON PHARMACEUTICALS, INC.

By: 
Name: Linda A. LaGorga
Title: SVP, Treasurer

DOW PHARMACEUTICAL SCIENCES, INC.

By: 
Name: Linda A. LaGorga
Title: SVP, Treasurer

MEDICIS PHARMACEUTICAL CORPORATION

By: 
Name: Linda A. LaGorga
Title: SVP, Treasurer


OBAGI MEDICAL PRODUCTS, INC.

By: 
Name: Linda A. LaGorga
Title: Treasurer


OMP, INC.

By: 
Name: Linda A. LaGorga
Title: Treasurer


ORAPHARMA, INC.

By: 
Name: Linda A. LaGorga
Title: SVP, Treasurer


PRECISION DERMATOLOGY, INC.

By: 
Name: Linda A. LaGorga
Title: SVP, Treasurer


SALIX PHARMACEUTICALS, INC.

By: 
Name: Linda A. LaGorga
Title: SVP, Treasurer


SALIX PHARMACEUTICALS, LTD.

By: 
Name: Linda A. LaGorga
Title: SVP, Treasurer


SANTARUS, INC.

By: 
Name: Linda A. LaGorga
Title: SVP, Treasurer

SOLTA MEDICAL, INC.

By: 
Name: Linda A. LaGorga
Title: SVP, Treasurer

VALEANT CANADA LP, by its General Partner
VALEANT CANADA GP LIMITED

By: 
Name: Robert R. Chai-Onn
Title: EVP, General Counsel

VALEANT PHARMACEUTICALS
INTERNATIONAL, INC.

By: Linda A. LaGorga
Name: Linda A. LaGorga
Title: SVP, Treasurer

VALEANT HOLDINGS IRELAND (AS
SUCCESSOR TO VALEANT INTERNATIONAL
BERMUDA)

By: Roger McGrath
Name: Roger McGrath
Title: Director

VALEANT PHARMACEUTICALS NORTH
AMERICA LLC

By: Linda A. LaGorga
Name: Linda A. LaGorga
Title: SVP, Treasurer

VALEANT PHARMACEUTICALS IRELAND

By: Roger McGrath
Name: Roger McGrath
Title: Director

Accepted and Agreed:
BARCLAYS BANK PLC,
as Collateral Agent

By: 

Name: Craig J. Malloy
Title: Director

SCHEDULE A
to
PATENT SECURITY AGREEMENT

PATENTS AND PATENT APPLICATIONS

<u>OWNER</u>	<u>TITLE</u>	<u>APP. NO.</u>	<u>APP. DATE</u>	<u>PATENT NO.</u>	<u>GRANT DATE</u>
Valeant Pharmaceuticals International	Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto	08/459151	6/2/1995	6683046	1/27/2004
Aton Pharma, Inc. And Louisiana State University And Agricultural And Mechanical College	Ocular drug delivery devices	14/087864	11/22/2013		
Aton Pharma, Inc.	Stereo selective synthesis of metyrosine	14/455116	8/8/2014		
Bausch & Lomb Incorporated	Sterilization of intraocular lenses	13/666051	11/1/2012	8753389	6/17/2014
Bausch & Lomb Incorporated	Ophthalmic surgical cassette and system	13/539886	7/2/2012	8512014	8/20/2013
Bausch & Lomb Incorporated	Packaging solutions	13/917734	6/14/2013		
Bausch & Lomb Incorporated	Polymorphs of brimonidine pamoate	13/826496	3/14/2013	8637514	1/28/2014
Bausch & Lomb Incorporated	Polymorphs of brimonidine pamoate	13/826516	3/14/2013	8637515	1/28/2014
Bausch & Lomb Incorporated	Ethylenically unsaturated polymerizable group comprising polycarbosiloxane monomers	13/841145	3/15/2013	9039174	5/26/2015
Bausch & Lomb Incorporated	Method and system of measuring toric lens axis angle	14/630700	2/25/2015		
Bausch & Lomb Incorporated	Contact lenses having hybrid orientation features	13/481041	5/25/2012	8690320	4/8/2014
Bausch & Lomb Incorporated	System and method of calculating visual performance of an ophthalmic optical correction using simulation of imaging by a population of eye optical systems	13/670968	11/7/2012	9091864	7/28/2015
Bausch & Lomb Incorporated	Irrigation sleeve and phacoemulsification needle with sleeve retention features	13/661493	10/26/2012		
Bausch & Lomb Incorporated	Ophthalmic compositions with biguanide and peg-glycerol esters	13/886571	5/3/2013	8889160	11/18/2014

Bausch & Lomb Incorporated	Ophthalmic compositions with alkoxylated natural waxes	14/377460	8/7/2014	9375401	06/28/2016
Bausch & Lomb Incorporated	Method for preparing suspensions of low-solubility materials	14/519776	10/21/2014		
Bausch & Lomb Incorporated	Sterile hyaluronic acid solutions	13/564161	8/1/2012	8530641	9/10/2013
Bausch & Lomb Incorporated	Fluoroquinolone carboxylic acid molecular crystals	13/826469	3/14/2013	8604020	12/10/2013
Bausch & Lomb Incorporated	Method and apparatus for determining depth of focus of an eye optical system	13/655048	10/18/2012	8931900	1/13/2015
Bausch & Lomb Incorporated	Peroxide contact lens care solution	13/835237	3/15/2013		
Bausch & Lomb Incorporated	Method of preparing water extractable silicon-containing biomedical devices	13/722073	12/20/2012	8967799	3/3/2015
Bausch & Lomb Incorporated	Vibrating surgical device for removal of vitreous and other tissue	14/020386	9/6/2013		
Bausch & Lomb Incorporated	Method of making a fully polymerized UV blocking silicone hydrogel lens	13/480651	5/25/2012		
Bausch & Lomb Incorporated	Intraocular lens injector assembly including a shuttle and method of using same	13/606362	9/7/2012		
Bausch & Lomb Incorporated	Poly(nitrogen/amine) derivatives of a natural wax and ophthalmic compositions	14/161936	1/23/2014	9279095	3/8/2016
Bausch & Lomb Incorporated	Light absorbing compounds for optical polymers	14/415697	1/19/2015	9249249	2/2/2016
Bausch & Lomb Incorporated	Fully polymerized UV blocking silicone hydrogel lens	13/480648	5/25/2012	8807745	8/19/2014
Bausch & Lomb Incorporated	Fully polymerized UV blocking silicone hydrogel lens	13/722054	12/20/2012	9075187	7/7/2015
Bausch & Lomb Incorporated	Minimizing biological lipid deposits on contact lenses	14/427928	3/12/2015		
Bausch & Lomb Incorporated	Method and apparatus for delaying polymerization	14/772106	3/13/2014		
Bausch & Lomb Incorporated	Hand held magnifier	29/436023	10/31/2012	D702746	4/15/2014
Bausch & Lomb Incorporated	Hand held magnifier	29/436021	10/31/2012	D702745	4/15/2014
Bausch & Lomb Incorporated	Ophthalmic compositions with wax esters	14/416229	1/21/2015		
Bausch & Lomb Incorporated	Ophthalmic compositions with omega-3 fatty acids	14/416154	1/21/2015		
Bausch & Lomb Incorporated	Ophthalmic multiple wavelength laser illuminator with a graphical user interface	14/072859	11/6/2013		

Bausch & Lomb Incorporated	Hingeless cartridge for use with an intraocular lens injector providing haptic control	13/673330	11/9/2012	9155615	10/13/2015
Bausch & Lomb Incorporated	Hingeless cartridge for intraocular lens injector providing haptic control	14/075845	11/8/2013	9237947	1/19/2016
Bausch & Lomb Incorporated	Hydrogel monomer mix containing added water	13/957497	8/2/2013		
Bausch & Lomb Incorporated	Use of an optical system simulating behavior of human eye to generate retinal images and an image quality metric to evaluate same	13/952795	7/29/2013	9001316	4/7/2015
Bausch & Lomb Incorporated	Synthesis of free radical polymerizable ethylenically unsaturated poloxamers and poloxamines	14/308229	6/18/2014	9309357	4/12/2016
Bausch & Lomb Incorporated	Ultrasonic vitrectomy needle	14/513459	10/14/2014		
Bausch & Lomb Incorporated		14/690791	4/20/2015		
Bausch & Lomb Incorporated		15/006525	1/26/2016		
Bausch & Lomb Incorporated ¹	Aqueous liquid composition containing 2-amino-3-(4-bromobenzoyl) phenylacetic acid	14/082662	11/18/2013		
Dendreon Corporation ²	Compositions and methods for the treatment of disease associated with TRP-P8 expression	14/604543	1/23/2015		
Dendreon Pharmaceuticals, Inc.		62/242113	10/15/2015		
Dow Pharmaceutical Sciences, Inc.	Pharmaceutical formulations containing corticosteroids for topical administration	14/340367	7/24/2014		
Dow Pharmaceutical Sciences, Inc.	Stabilized efinaconazole compositions	14/505379	10/2/2014		
Dow Pharmaceutical Sciences, Inc.	Pharmaceutical formulations containing corticosteroids for topical administration	13/287176	11/2/2011	8809307	8/19/2014
Dow Pharmaceutical Sciences, Inc.	Anti-infective methods, compositions, and devices	14/552307	11/24/2014		
Dow Pharmaceutical Sciences, Inc.	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent	13/869494	4/24/2013	8663699	3/4/2014

¹ Record ownership to be updated to B&L Pharma Holding.

² Assignment to Dendreon Pharmaceuticals, Inc. needs to be recorded

Dow Pharmaceutical Sciences, Inc.	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent	14/260211	4/23/2014		
Dow Pharmaceutical Sciences, Inc.	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent	14/065186	10/28/2013	8895070	11/25/2014
Dow Pharmaceutical Sciences, Inc.	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent	14/065199	10/28/2013	9078870	7/14/2015
Dow Pharmaceutical Sciences, Inc.	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent	13/613401	9/13/2012		
Dow Pharmaceutical Sciences, Inc.	Method for obtaining a stable dispersion of benzoyl peroxide	13/352712	1/18/2012		
Dow Pharmaceutical Sciences, Inc.	Kinetin/zeatin topical formulation	14/216722	3/17/2014		
Dow Pharmaceutical Sciences, Inc.	Compositions and methods for treating diseases of the nail	13/199717	9/7/2011	8486978	7/16/2013
Dow Pharmaceutical Sciences, Inc.	Compositions and methods for treating diseases of the nail	13/943165	7/16/2013	9302009	4/5/2016
Dow Pharmaceutical Sciences, Inc.	Compositions and methods for treating diseases of the nail	14/491889	9/19/2014		
Dow Pharmaceutical Sciences, Inc.	Compositions and methods for treating diseases of the nail	14/755699	6/30/2015		
Dow Pharmaceutical Sciences, Inc.		13/478249	5/23/2012		
Medicis Pharmaceutical Corporation	Controlled release pharmaceutical dosage forms	13/890173	5/8/2013		
Medicis Pharmaceutical Corporation	Topical compositions of flunisolide and methods of treatment	14/213530	3/14/2014		
Medicis Pharmaceutical Corporation	Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy	13/895305	5/15/2013		
Medicis Pharmaceutical Corporation	Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy	14/091589	11/27/2013	9271973	3/1/2016
Medicis Pharmaceutical Corporation	Pump systems and methods for storing and dispensing a plurality of precisely measured unit-doses of imiquimod cream	14/641089	3/6/2015		

Medicis Pharmaceutical Corporation	Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts	14/091965	11/27/2013	9078889	7/14/2015
Medicis Pharmaceutical Corporation	Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts	14/796296	7/10/2015		
Medicis Pharmaceutical Corporation	Methods for controlling formation of imiquimod impurities for two months, four months, and six months	12/698132	2/1/2010	7902246	3/8/2011
Medicis Pharmaceutical Corporation		13/672520	11/8/2012		
Medicis Pharmaceutical Corporation		13/536130	6/28/2012		
Medicis Pharmaceutical Corporation		13/659789	10/24/2012		
Obagi Medical Products, Inc.	Stable organic peroxide compositions	11/372958	3/10/2006	7390431	6/24/2008
Obagi Medical Products, Inc.	Stable organic peroxide compositions	12/144162	6/23/2008	7560119	7/14/2009
Obagi Medical Products, Inc.	Stable organic peroxide compositions	11/986442	11/21/2007	7445729	11/4/2008
Obagi Medical Products, Inc.	Stable organic peroxide compositions	12/264517	11/4/2008	7556820	7/7/2009
Obagi Medical Products, Inc.	Chemical compositions and methods of making them	11/647623	12/29/2006	7687650	3/30/2010
Obagi Medical Products, Inc.	Chemical compositions and methods of making them	11/668020	1/29/2007	7897800	3/1/2011
Obagi Medical Products, Inc.	Chemical compositions and methods of making them	12/709044	2/19/2010	8148563	4/3/2012
Obagi Medical Products, Inc.	Anti-aging treatment method using copper and zinc compositions	11/452642	6/14/2006	7927614	4/19/2011
Obagi Medical Products, Inc.	Method of wound/burn healing using copper-zinc compositions	11/648278	12/29/2006	7867522	1/11/2011
Obagi Medical Products, Inc.	Rosacea treatments using polymetal complexes	14/026592	9/13/2013		
Obagi Medical Products, Inc.	Compositions, kits and regimens for the treatment of skin, especially décolletage	12/331781	12/10/2008	8273791	9/25/2012
Obagi Medical Products, Inc.	Compositions, kits and regimens for the treatment of skin, especially décolletage	13/593184	8/23/2012	8505730	8/13/2013
Obagi Medical Products, Inc.	Rosacea treatments and kits for performing them	13/368915	2/8/2012		
Obagi Medical Products, Inc.	Rosacea treatments and kits for performing them	13/144833	1/22/2016		
OMP, Inc.	Methods for lightening skin using arbutin compositions	14/849413	9/9/2015		

OMP, Inc.	Stable skin care compositions and methods for manufacturing them	13/942419	7/15/2013		
OMP, Inc.	Topical compositions and methods for manufacturing them in specifically treated steel vessels	13/942445	7/15/2013		
Orapharma, Inc.	Medicinal implant device and cartridge	13/975898	8/26/2013		
PreCision Dermatology, Inc.	Modulation of zinc levels to improve tissue properties	14/603932	1/23/2015		
PreCision Dermatology, Inc.	Topical treatment of localized scleroderma	14/897516	12/10/2015		
Salix Pharmaceuticals, Inc. and Alfa Wassermann S.P.A	Rifaximin derivative and uses thereof	14/707858	5/8/2015	9364467	6/14/2016
Salix Pharmaceuticals, Inc.	Use of aminosalicylates in diarrhoea-predominant irritable bowel syndrome	14/585911	12/30/2014		
Salix Pharmaceuticals, Inc.	Laxative compositions and methods for treating constipation and related gastrointestinal diseases and conditions	14/424515	2/27/2015		
Salix Pharmaceuticals, Inc.	Methods of administering rifaximin without producing antibiotic resistance	14/629873	2/24/2015		
Salix Pharmaceuticals, Inc.	Methods of improving long-term survival and reducing hospitalization readmission rates for subjects suffering from hepatic encephalopathy	14/629871	2/24/2015		
Salix Pharmaceuticals, Inc.	Methods of administering rifaximin for weight loss and treatment of obesity	14/629869	2/24/2015		
Salix Pharmaceuticals, Inc.	Method of treating ulcerative colitis	14/282888	5/20/2014		
Salix Pharmaceuticals, Inc.	Method for treating ulcerative colitis	14/448872	7/31/2014		
Salix Pharmaceuticals, Inc.	Method of treating ulcerative colitis	14/529012	10/30/2014		
Salix Pharmaceuticals, Inc.	Prevention, treatment, and amelioration of radiation induced enteritis	14/731692	6/5/2015		
Salix Pharmaceuticals, Inc.	Methods for treating bowel disease	14/799018	7/14/2015		
Salix Pharmaceuticals, Ltd. and Progenics Pharmaceuticals, Inc. & Radius Product Development, Inc.	Automatic injection device	29/422358	5/18/2012	D715422	10/14/2014
Salix Pharmaceuticals, Ltd.	Methods of using rifaximin in position emission tomography (pet) scans	14/933253	11/5/2015		
Salix Pharmaceuticals, Ltd.		14/882934	10/14/2015		
Salix Pharmaceuticals, Ltd.	Forms of Rifaximin and Uses Thereof	14/995791	8/16/2012		

Salix Pharmaceuticals, Inc.		62/294405	2/12/2016		
Santarus, Inc.	Selection and treatment of subjects	13/981699	10/3/2013		
Santarus, Inc.	Anti-VLA1 (CD49A) antibody pharmaceutical compositions	14/379095	8/15/2014		
Santarus, Inc.	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them	14/673670	3/30/2015		
Solta Medical, Inc.	Apparatus for transcutaneously treating tissue	14/074927	11/8/2013		
Valeant Canada LP	Activation of innate and adaptive immune responses by a ginseng extract	13/846267	3/18/2013	9050313	6/9/2015
Valeant Canada LP	Use of a ginseng extract to prevent and treat alopecia areata	14/353231	4/21/2014		
Valeant Pharmaceuticals International, Inc.	Compounds having selective activity for retinoid x receptors, and means for modulation of processes mediated by retinoid x receptors	08/472784	6/7/1995	5962731	10/5/1999
Valeant Pharmaceuticals International, Inc. & The University of British Columbia	Ethylene glycol esters as photoactive agents	09/088524	6/1/1998	5929105	7/27/1999
Valeant Pharmaceuticals International, Inc. & The University of British Columbia	Ethylene glycol esters as photoactive agents	09/313106	5/17/1999	6153639	11/28/2000
Valeant Pharmaceuticals International, Inc. & The University of British Columbia	Ethylene glycol esters as photoactive agents	09/588206	6/6/2000	6756396	6/29/2004
Valeant Pharmaceuticals International, Inc.	Ethylene glycol esters as photoactive agents	10/825270	4/14/2004	7122569	10/17/2006
Valeant Pharmaceuticals International, Inc.	Model and method of angiogenesis inhibition	09/169735	10/9/1998	6117862	9/12/2000
Valeant Pharmaceuticals International, Inc. and University of British Columbia	Immuno-adjuvant PDT treatment of metastatic tumors	10/985582	11/9/2004	7850981	12/14/2010
Valeant Pharmaceuticals International, Inc.	Reduced fluence rate PDT	10/072009	2/6/2002	6800086	10/5/2004
Valeant Pharmaceuticals International, Inc.	Reduced fluence rate PDT	10/641885	8/14/2003	7753943	7/13/2010
Valeant Pharmaceuticals International, Inc.	Method for reducing or preventing PDT related inflammation	10/081010	2/15/2002	8106038	1/31/2012
Valeant Pharmaceuticals International, Inc.	Compositions and methods for delivery of photosensitive drugs	10/440505	5/15/2003	7455858	11/25/2008
Valeant Pharmaceuticals International, Inc.	Formulations of calcium and phosphate for oral inflammation	14/945865	11/19/2015		

Valeant Pharmaceuticals International, Inc.	Compositions and methods for teeth whitening	15/006943	1/26/2016		
Valeant Pharmaceuticals North America		15/173961	6/18/2016		
Valeant Pharmaceuticals International, Inc. and Novartis Ophthalmics AG	Methods, compositions and articles for reducing or preventing the effects of inflammation	08/942883	10/2/1997	6274614	8/14/2001
Valeant Pharmaceuticals International, Inc. and Novartis Ophthalmics AG	Methods, compositions and articles for reducing or preventing the effects of inflammation	09/929558	8/13/2001	6677366	1/13/2004
Valeant Pharmaceuticals International, Inc.	Treatment of macular edema	10/622310	7/17/2003	7015240	3/21/2006
Valeant Pharmaceuticals International, Inc. and University of British Columbia	Use of photodynamic therapy for prevention of secondary cataracts	08/762854	12/10/1996	6043237	3/28/2000
Valeant Pharmaceuticals International, Inc. and University of British Columbia	Use of photodynamic therapy for prevention of secondary cataracts	09/536291	3/27/2000	6248734	6/19/2001
Valeant Pharmaceuticals International, Inc.	Drug delivery system for hydrophobic drugs	09/833406	4/11/2001	6984395	1/10/2006
Valeant Pharmaceuticals International, Inc.	Drug delivery system for hydrophobic drugs	12/487964	6/19/2009	8852629	10/7/2014
Valeant Pharmaceuticals International, Inc.	Method for treating neovascularization	13/448242	4/16/2012	8862224	10/14/2014
Valeant Pharmaceuticals International, Inc.	Photodynamic therapy for conditions of the eye	13/140411	11/7/2011	9226917	1/5/2016
Valeant Pharmaceuticals International, Inc.	Controlled release micro particles	14/489863	9/18/2014		
Valeant Pharmaceuticals International	Benzyloxy anilide derivatives useful as potassium channel modulators	13/483018	5/29/2012	8492588	7/23/2013
Valeant Pharmaceuticals International, Inc.	Device and method for teeth brightening	13/863529	4/16/2013		
Valeant Pharmaceuticals International ³	Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto	08/459151	6/2/1995	6683046	1/27/2004
Valeant Pharmaceuticals International, Inc.	A multi dose package, course and method of treatment for delivering predetermined multiple doses of a pharmaceutical	14/629176	2/23/2015		
Valeant Pharmaceuticals International, Inc.	Balloon catheter for photodynamic therapy	08/649439	5/17/1996	6013053	1/11/2000
Valeant Pharmaceuticals International, Inc.	Method for treating neovascularization	11/975325	10/18/2007	8158669	4/17/2012

³ Missing assignment to Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc.	Photodynamic therapy of occult age-related macular degeneration	10/072272	2/6/2002	8034803	10/11/2011
Valeant Pharmaceuticals International, Inc. and Novartis AG	Method to prevent vision loss	10/072215	2/6/2002	7060695	6/13/2006
Valeant Pharmaceuticals International, Inc.	Photodynamic therapy laser	13/426470	3/21/2012	9211214	12/15/2015
Valeant Pharmaceuticals International, Inc.	Photodynamic therapy laser	14/872248	10/1/2015		
Valeant Pharmaceuticals International, Inc.	Treatment of macular edema	10/199662	7/19/2002	6599891	7/29/2003
Valeant International Bermuda	Modified release formulations of a bupropion salt	14/474580	9/2/2014		
Valeant International Bermuda	Bupropion hydrobromide polymorphs	13/653503	10/17/2012	8604085	12/10/2013
Valeant Sp. Z.O.O. Sp. J. ⁴	Viscoelastic solutions containing sodium hyaluronate and hydroxypropyl methyl cellulose, preparation and uses	11/791603	12/10/2007		
Valeant Sp. Z.O.O. Sp. J.	Use of a viscoelastic fluid for producing a medicinal product for surgically treating the eye	14/002438	8/30/2013		
Valeant Sp. Z.O.O. Sp. J.	Injector for a flexible implant	10/606634	6/26/2003	7226455	6/5/2007
Valeant Sp. Z.O.O. Sp. J.	Fundus camera objective and camera having such fundus camera objective	12/864421	9/20/2010	8393735	3/12/2013
Valeant Sp. Z.O.O. Sp. J.	Method for producing a container welded in a protective cover	13/881686	5/14/2013		
Dow Pharmaceutical Sciences, Inc.	Compositions for increasing solubility of azole drug compounds that are poorly soluble in water	13/855034	4/2/2013	8877792	11/4/2014
Valeant Pharmaceuticals International, Inc.	Teeth whitening composition and methods	11/598206	11/9/2006	8075875	12/13/2011
Valeant Pharmaceuticals International, Inc.	Photopolymerization material for gums isolation	12/525890	3/1/2010	8334328	12/18/2012
Salix Pharmaceuticals, Ltd.	Forms of rifaximin and uses thereof	14/816333	8/3/2015		

⁴ Valeant Sp. Z.O.O. Sp. J. patents are owned by Valeant Pharmaceuticals Ireland, record ownership to be updated